Treatment of thyroid dysfunction in a medical specialist’s office – the role of levothyroxine Review article
Article Sidebar
Main Article Content
Abstract
Synthetic levothyroxine is the first line treatment for hypothyroidism, one of the most common endocrine disorders, independently its cause, in all age groups. The Polish Endocrinological Society, together with European Thyroid Association, American Thyroid Association and American Association of Clinical Endocrinologists, do not recommend the use of dried thyroid preparations, triiodothyronine or combined preparations of thyroxine with triiodothyronine. The objective of treatment is to achieve biochemical and clinical euthyroidism monitored by TSH and/or FT4 levels. The daily dose of levothyroxine depends on many factors, including the etiology and severity of hypothyroidism, age, body weight, pregnancy and comorbidities. Routinely, levothyroxine is administered on an empty stomach at least 30 minutes before breakfast (ATA 2014 recommend up to 60 minutes interval between meal and taking the drug). Levothyroxine can also be used in combination therapy in Graves’ disease. Currently, the routine use of synthetic sodium levothyroxine in patients with multinodular goiter is not recommended because it increases the risk of osteoporosis in postmenopausal women and atrial fibrillation in patients after 60 year of life.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Gietka-Czernel M. Niedoczynność tarczycy. In: Zgliczyński W. Endokrynologia – część pierwsza. Wielka Interna – 2nd ed. Medical Tribune, Warszawa 2020: 258-70.
3. Pearce SHS, Brabant G, Duntas LH et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4): 215-28. http://doi.org/10.1159/000356507.
4. Jastrzębska H. Leczenie hormonami tarczycy – czy to wyzwanie? Postępy Nauk Medycznych. 2015; 12: 835-8.
5. Jonklaas J, Bianco AC, Bauer AJ et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014; 24(12): 167-751.
6. Persani L, Brabant G, Dattani M et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. Eur Thyroid J. 2018; 7(5): 225-37. http://doi.org/10.1159/000491388.
7. Alexander EK, Pearce EN, Brent GA et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017; 27(3): 315-89.
8. Virili C, Antonelli A, Santaguida MG et al. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev. 2019; 40(1): 118-36. http://doi.org/10.1210/er.2018-00168.
9. Skelin M, Lucijanić T, Amidžić Klarić D et al. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. 2017; 39(2): 378-403. http://doi.org/10.1016/j.clinthera.2017.01.005.
10. Boelaert K, Visser WE, Taylor PN et al. Endocrinology in the time of COVID-19: Management of hyperthyroidism and hypothyroidism. Eur J Endocrinol. 2020; 183(1): G33-G9. http://doi.org/10.1530/EJE-20-0445.
11. Matyjaszek-Matuszek B, Woźniak M, Ochmańska A et al. Selected thyreology problems during the COVID-19 pandemic. Hypothyroidism and hyperthyroidism did anything change? Endokrynol Pol. 2021; 72(2): 170-8. http://doi.org/10.5603/EP.a2021.0013.
12. Cooper DS, Doherty GM, Haugen BR et al. Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2010; 19: 1167-214. Erratum: 2010; 20: 674-5.
13. Franklyn JA, Betteridge J, Daykin J et al. Long-term thyroxine treatment and bone mineral density. Lancet. 1992; 340: 9-13.
14. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994; 331(19): 1249-52.